In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck KGAA to pay over $7bn for Millipore

Executive Summary

In an effort to boost its laboratory business and strengthen its US presence, Merck KGAA has agreed to pay $107 per share to acquire all of publicly traded life sciences firm Millipore. Including net debt of $1.2bn, the deal is valued at about $7.2bn. The per-share price represents a 54% premium to Millipore's stock value in the ten days preceding the company's announcement that it was exploring strategic business alternatives, such as a potential sale.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies